ROLE OF STATINS IN CONTROLLING COUGH AND IMPROVING LUNG FUNCTION AND EXERCISE CAPACITY IN BRONCHIECTASIS PATIENTS.

Abdul Rauf¹, Syed Sarmad Ali Naqvi², Muhammad Imran Sharif³, Masood Alam⁴, Muhammad Imran Shehzad⁵

ABSTRACT... Objectives: To investigate the role of high dose atorvastatin in controlling cough improving lung function and exercise capacity in patients with bronchiectasis. Study Design: Cross Sectional Study. Setting: Respiratory unit of Nishtar hospital Multan. Period: January 2016 to September 2018. Material & Methods: Total 58 patients were enrolled having clinically significant bronchiectasis having productive cough and were clinically stable. Consecutive sampling was done and patients were divided into two groups by lottery method. Group A received high dose atorvastatin 80mg once daily for 6 months and group B received placebo for 6 months. Patients in both groups received other standard medical treatment. Results: The mean FEV₁, FVC, FEV₂/FVC, WBC, CRP and LCQ score unit for the statin group was 2.44±0.73 L, 3.36±0.84 L, 67.42±6.21, 6.94±1.89×10⁹ cells per L, 6.35±1.21 mg/L and 15.40±3.62 respectively. While, the mean FEV₁, FVC, FEV₂/FVC, WBC, CRP and LCQ score unit for the placebo group was 2.10±0.86 L, 2.82±1.11 L, 67.31±3.09, 6.53±2.55×10⁹ cells per L, 9.21±6.39 mg/L and 13.56±2.73 respectively. The difference was statistically significant for FVC (p=0.038), CRP (p=0.022) and LCQ score units (p=0.033). The mean FEV₁, FVC, FEV₁/FVC, improvement in 6MWT and improvement in LCQ scores units for the statin group was 0.0517±0.31 L, -0.0172±0.32 L, 0.000±0.20, -0.1354±0.48 m and 2.2±1.08 units respectively. Improvement in LCQ score> 1.3 units was observed in n=7 (24.1%) patients. While, the mean FEV₁, FVC, FEV₁/FVC, improvement in 6MWT and improvement in LCQ scores units for the placebo group was 0.061±0.24 L, -0.0483±0.30 L, 0.179±0.29, 0.001±0.47 m and -0.7214±0.25 units respectively. Improvement in LCQ score> 1.3 units was observed in n=12 (41.4%) patients. The difference was statistically significant for improvement in LCQ score units (p=0.000). Conclusion: Statins can be used in controlling the cough in patients with bronchiectasis. But its role in improving lung function test and exercise capacity need further research and investigation.

Key words: Atorvastatin, Bronchiectasis, Lung Function, Cough, Statins.

INTRODUCTION
Bronchiectasis chronic respiratory disease, caused by permanent dilatation of bronchioles and is characterized by recurrent chest infection productive cough and shortness of breath. Bronchiectasis is not a rare disease but however it is regarded as orphan disease because of Limited research and trials. In this era of CT scan the exact incidence of bronchiectasis is not available. There is poor understanding about pathogenesis of bronchiectasis hot but histopathology shows increase neutrophilic inflammation. Almost two thirds patients of bronchiectasis are chronically infected.¹ Increased level of neutrophilic inflammation in the airways cause bronchial wall damage and enhance chances of bacterial infection.² C reactive protein which is systemic inflammatory marker is increased in bronchiectasis and directly related to severity of disease and inversely related to quality of life and lung function in stable bronchiectasis.³ Evidence based data is limited in treatment of this disease. Currently Physiotherapy of chest and long term use of antibiotics is approach in which disorder. Continuous use of antibiotics raised
many concerns because it causes side effects Health Care associated infection and resistance. Because of these concerns research is underway to investigate the role of anti-inflammatory agents in bronchiectasis.

Pleiotropic effects of statins such as decreasing the inflammation and enhancing the adoptive and emanate immune system.\textsuperscript{4,5} Statins decrease recruitment of neutrophils in human and animal experimental system in sterile inflammation.\textsuperscript{6,7} Use of high dose statins in treatment of Pulmonary infection with staphylococcus in murine models caused increased production of DNA traps extracellularly by engulfing within the lungs and increased protection against infection dissemination.\textsuperscript{6,9} Use of high dose simvastatin for long period has dose dependent protection against pneumonia.\textsuperscript{10}

Anti-inflammatory effect of statins had been investigated in other respiratory diseases. But there is limited delta about use of statins in bronchiectasis. In this study v have investigated the role of statins in improving quality of life and functional status of bronchiectasis patients. This research will encourage more curiosity about use of stations in bronchiectasis and will encourage more investigation in this topic.

**MATERIAL & METHODS**

This is a cross sectional study conducted from January 2016 to September 2018. In this investigation total 58 patients were enrolled from outdoor of respiratory unit of Nishtar hospital Multan. Patients were having clinically significant bronchiectasis having productive cough and were clinically stable. Patient’s disease were confirmed by HRCT chest and having history of one or more acute exacerbation of bronchiectasis were included from 15 to 65 years old age. Consecutive sampling was done and patients were divided into two groups by lottery method. Group-A received high dose atorvastatin 80mg once daily for 6 months and group B received placebo for 6 months. Patients in both groups received other standard medical treatment. Consent was taken from these patients and approval was taken of this research from ethical committee. Patients having history of COPD, uncontrolled asthma, heavy smoking history, cystic fibrosis, diffuse parenchymal lung disease, decompensated liver disease and allergic pulmonary aspergillosis were excluded from study. Patients having chronic infection with pseudomonas aeruginosa and emphysematous changes on HRCT chest were also excluded. Sample size calculated by reference study in which cough improved in 40% patients using atorvastatin as compared to placebo in which 17% patient’s improved.\textsuperscript{11}

Patients selected in this study were examined and analyzed at baseline after enrolling in this research. Spirometry was done and FEV1, FVC and FEV1/FVC were documented pre bronchodilation. Functional status was checked also by 6minute walk test and recording distance covered at baseline. Both spirometry and 6-minute walk distance were also checked after 6 months of treatment in both groups. Patient’s detailed history of asthma, smoking, occupation was also taken. Body mass index were documented and was auscultated. Vitals were recorded at baseline and blood sample was also drawn to check white blood cells, blood sugar and c reactive proteins.

Cough was assessed at baseline by self-filling Leicester Cough Questionnaire (LCQ). This questioner has total score of 3 to 21 in which lower score indicates severe cough. This assessment was also done after 6 months. Minimum improvement of 1.3 units in this score was taken as significant improvement in cough.

Data was analyzed by SPSS volume 22. Qualitative variables OD data like gender, age, smoking status were statistically calculated by percentage and chi square test was applied to check the significance. Quantitative variables like LCQ score, FEV1, FVC and its ratio and 6 minute walk test were calculated in mean and standard deviation and significance checked with t test. P value of less than .005 was considered significant.

**RESULTS**

Fifty-eight patients were included in this study, both genders. We study two groups i.e. statin and placebo respectively. The mean age and BMI statin
The mean FEV₁, FVC, FEV₂/FVC, WBC, CRP and LCQ score unit for the statin group was 2.44±0.73 L, 3.36±0.84 L, 67.42±6.21, 6.94±1.89×10⁹ cells per L, 6.35±1.21 mg/L and 15.40±3.62 respectively. While, the mean FEV₁, FVC, FEV₂/FVC, WBC, CRP and LCQ score unit for the placebo group was 2.10±0.86 L, 2.82±1.11 L, 67.31±3.09, 6.53±2.55×10⁹ cells per L, 9.21±6.39 mg/L and 13.56±2.73 respectively. The difference was statistically significant for FVC (p=0.038), CRP (p=0.022) and LCQ score units (p=0.033). (Table-II).

The mean FEV₁, FVC, FEV₂/FVC, improvement in 6MWT and improvement in LCQ scores units for the statin group was 0.0517±0.31 L, -0.0172±0.32 L, 0.000±0.20, -0.1354±0.48 m and 2.2±1.08 units respectively. Improvement in LCQ score> 1.3 units was observed in n=7 (24.1%) patients. While, the mean FEV₁, FVC, FEV₂/FVC, improvement in 6MWT and improvement in LCQ scores units for the placebo group was 0.061±0.24 L, -0.0483±0.30 L, 0.179±0.29, 0.001±0.47 m and -0.7214±0.25 units respectively. Improvement in LCQ score> 1.3 units was observed in n=12 (41.4%) patients. The difference was statistically significant for improvement in LCQ score units (p=0.000). (Table-III).
DISCUSSION
Results of study showed that patients in statin group using high dose statin improved in over all cough measured by LCQ score. This improvement was also statistically significant from baseline. While in control group improvement in cough was not significant. While in both groups that is case and control improvement in FEV1, FVC and ration of these was not significant. And functional capacity measured by 6-minute walk distance was also not improved in both groups.

Bronchiectatic lung secretions are result of chemotactic activity of leukotriene B4 and interleukin 8. Statins have immunomodulatory effect and it has been studied in many chronic lung diseases. In study done by Wang et al. showed that statins cause fewer exacerbations in chronic obstructive pulmonary disease. Statin also decrease risk of death by 39% in chronic obstructive lung disease. In study done by Li et al. showed that use of statin after surgery of lung transplantation improved maintenance of graft-lung function, improved survival and delay the onset of bronchiolitis obliterans.

There is increased airway inflammation in bronchiectasis due to neutrophil persistence for longer period. There is regulation of inflammation by programmed cell death or apoptosis. Apoptosis is a major process of neutrophils death and it life can be extended and functional activity of neutrophils can be improved by cytokines such as interferon gamma, granulocyte-macrophages stimulating factor, granulocyte colony stimulating factor and interleukin.

Neutrophilic apoptosis showed that it stimulated inflammation resolution and fast recovery in vivo model in pneumococcal infection. Statins caused decreased amount of BCL2 which is an anti-apoptotic protein in cancer cell lines in human as well in murine non cancer cell lines. Statins also enhanced efferocytosis in vivo, that has important role in disease in which this process is impaired.

Statins role in enhancing neutrophilic apoptosis in airways or process by which it increases apoptosis of neutrophils in patient’s sputum with bronchiectasis should be fully investigated. It is of great therapeutic potential by which activated neutrophils are switched off and neutrophils underwent apoptosis in bronchiectasis by enhancing resolution of inflammation.

Statins also has antithrombotic effects and causes reduction in endothelial dysfunction in sepsis in animal models that improves outcome. No adverse effects of statins documented in viable bacterial load sputum.

Investigations and research until now suggest the treatment with statins in bronchiectasis for longer period and macrolides for anti-inflammatory approach. Randomized controlled trials in bronchiectasis investigated role of macrolides. Results of these trials showed that macrolides in full dose or low dose for 6 to 24 months caused decrease in frequency of exacerbation.

In this study results showed that statins improved cough in patients who used high dose of atorvastatin as compared to placebo group. But lung function test and exercise capacity were not improved in both groups.

Limited sample size and no long term follow up of the patients were limitation of this study.

CONCLUSION
Statins can be used in controlling the cough in patients with bronchiectasis. But its role in improving lung function test and exercise capacity need further research and investigation.

Copyright© 11 Oct, 2019.

REFERENCES


9. Cheng L. Relevance of neutrophils and neutrophil extracellular traps in bronchiolitis obliterans syndrome of patients receiving stem cell therapy (Doctoral dissertation, University of Toronto (Canada)).


19. WG Wood, U Igavbooa, WE Muller, GP Eckert Bcl-2, and apoptosis: Cell death or cell protection?


## AUTHORSHIP AND CONTRIBUTION DECLARATION

<table>
<thead>
<tr>
<th>Sr. #</th>
<th>Author(s) Full Name</th>
<th>Contribution to the paper</th>
<th>Author(s) Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Abdul Rauf</td>
<td>Conception &amp; Study design.</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Syed Sarmad Ali Naqvi</td>
<td>Data collection &amp; literature review.</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Muhammad Imran Sharif</td>
<td>Manuscript writing &amp; Data analysis.</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Masood Alam</td>
<td>Data collection &amp; Manuscript writing.</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>M. Imran Shehzad</td>
<td>Final approval &amp; Proof reading.</td>
<td></td>
</tr>
</tbody>
</table>